Study of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation

Registered drugNo placebo

Study of alpelisib and olaparib combination compared to chemotherapy in patients with platinum-resistant high-grade serous ovarian cancer without BRCA mutation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Alpelisib
Sponsor:Novartis Pharma AG

Contact Research Centre

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atorvastatin
Sponsor:Novartis Pharma GmbH

Contact Research Centre

Adenocarcinoma gastric+1

Not recruiting

Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

Registered drugNo placebo

Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Berlin

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, including studies of metastatic prostate cancer, colorectal cancer, and innovative approaches for breast cancer treatment.

Prostate Cancer Therapeutics
Colorectal Cancer Treatment
Early-Stage Breast Cancer
Bladder Cancer Interventions

Novel combination therapies and targeted treatments are being evaluated to improve patient outcomes across multiple cancer types.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting various viral infections, including studies on respiratory syncytial virus, cytomegalovirus, and herpes zoster.

RSV Vaccine Development
CMV Prevention
Yellow Fever Protection
Herpes Virus Management

These trials aim to enhance immune response and provide long-term protection against serious viral infections.

03 Chronic Conditions

Innovative treatments for various chronic conditions, including autoimmune dementia, hypertriglyceridemia, and studies in transplant medicine.

Neurological Disorders
Metabolic Conditions
Organ Transplantation
Women's Health

Research focuses on developing targeted therapies and improving treatment outcomes for long-term conditions.

Back to Germany All countries